Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | CPT2 | P23786 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7006067 | 0.93 | HDAC3 (0.49) | CYP2C19HIF1ATDP1MAPTRXFP1 | |
| SCHEMBL7011838 | 0.93 | HDAC3 (0.49) | CYP2C19HIF1ATDP1MAPTRXFP1 | |
| SCHEMBL14360509 | 0.93 | HDAC3 (0.49) | CYP2C19HIF1ATDP1MAPTRXFP1 | |
| SCHEMBL7006017 | 0.93 | HDAC3 (0.49) | CYP2C19HIF1ATDP1MAPTRXFP1 | |
| SCHEMBL6368028 | 0.85 | CYP2C19 (0.61) | CYP2C19HIF1AFFAR1CYP1A2MAPT | |
| SCHEMBL5522093 | 0.85 | ESR1 (0.52) | CYP2C19HIF1ATDP1FFAR1CPT2 | |
| SCHEMBL5524018 | 0.83 | FFAR1 (0.42) | CYP2C19HIF1ATDP1FFAR1CPT2 | |
| SCHEMBL5521505 | 0.83 | MIF (0.59) | TDP1FFAR1CPT2MAPTMIF | |
| SCHEMBL5529032 | 0.82 | CYP2C19 (0.46) | CYP2C19HIF1ATDP1CYP1A2MAPT | |
| SCHEMBL14360769 | 0.79 | HDAC3 (0.50) | TDP1MAPTRXFP1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | WARNER-LAMBERT COMPANY (US) | 2007-08-30 | — | — | US | disclosed |
| EP-1572189-A1 | METHOD OF LOWERING CRP AND REDUCING SYSTEMIC INFLAMMATION | Warner-Lambert Company LLC (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050026979-A1 | Methods for treating inflammation and inflammation-associated diseases with a statin and ether | GHAZZI MAHA (US) | 2005-02-03 | — | — | US | disclosed |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| US-20040167229-A1 | Method of lowering CRP and reducing systemic inflammation | BAKKER-ARKEMA REBECCA (US) | 2004-08-26 | — | — | US | disclosed |
| WO-2004045596-A1 | METHOD OF LOWERING CRP AND REDUCING SYSTEMIC INFLAMMATION | WARNER-LAMBERT COMPANY LLC (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | WARNER-LAMBERT COMPANY | 2004-03-11 | — | — | US | disclosed |
| US-4711896-A | ANTIDIABETIC, ANTILIPEMIC AGENTS | EPIS S.A. (CH) | 1987-12-08 | — | — | US | disclosed |
| US-4689344-A | ANTICHOLESTEROL AGENTS | EPIS S.A. (CH) | 1987-08-25 | — | — | US | disclosed |
| EP-0185080-A1 | — | EPIS SA | 1986-06-25 | — | — | EP | disclosed |
| WO-1986000298-A1 | ALPHA-, OMEGA-DICARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION AND MEDICINES COMPOSED THEREOF | EPIS S.A. (CH) | 1986-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048910-A1 | Dialkyl ether di-substituted with formyl, carboxy acid, ester and/or tetrazole, which are on tertiary carbon atoms, e.g., 6-(5-carboxy-5-methylhexyloxy)-2,2-dimethylhexanoic acid; lupus, connective tissue disease, sepsis, joint pain | TLR5, SSB, TLR4 | CYP2C19 2153/4885HIF1A 853/4885TDP1 2229/4885 |
| US-20070203212-A1 | METHOD OF TREATING OSTEOARTHRITIS | SYVN1, MMP13, TNF | CYP2C19 3480/4885HIF1A 230/4885TDP1 3613/4885 |
| US-20050026979-A1 | Methods for treating inflammation and inflammation-associated diseases with a statin and ether | HMGCR, CXCL8, DHCR7 | CYP2C19 573/4885HIF1A 1923/4885TDP1 3202/4885 |
| US-20050004196-A1 | Pharmaceutical compositions including an ether and selective COX-2 inhibitor and methods for using such | PTGES2, PTGES, PTGER2 | CYP2C19 99/4885HIF1A 4067/4885TDP1 4216/4885 |
| US-20040167229-A1 | Method of lowering CRP and reducing systemic inflammation | ALB, TTR, IL6 | CYP2C19 1114/4885HIF1A 3573/4885TDP1 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.